For James Paton's latest contributions to The Japan Times, see below:
Demand for the medications is poised to outpace supply as COVID-19 spreads around the globe and scientists question how well vaccines and antibody treatments will hold up against omicron.
Experts say it is critical to invest in a variety of approaches, including inoculations that could target multiple versions of the pathogen in a single shot.
Despite efforts to license molnupiravir to generic-drug firms, the same risks of unequal distribution remain, says report.
A year ago, scores of countries committed to COVAX, the program set up to deliver COVID-19 vaccines equitably to every corner of the planet. Now the initiative is falling short of its goals. Facing a 25% cut to COVAX’s supply forecast for the year, its ...
Wealthy countries face mounting pressure to divert COVID-19 vaccine supplies to lower-income regions.
Around the globe, people and governments are finding out that COVID-19 won’t be thrashed into extinction, but is more likely to enter a long, endemic tail.
As India grapples with a deadly surge among its population of 1.4 billion, worries are growing for many other spots all over the planet.
Some experts are worried about the potential impact of widely deploying Chinese shots that have demonstrated lower efficacy rates than those made by Pfizer and Moderna.
Reviews by U.K. and European Union regulators finding potential links to the unusual side effects are another blow for the shot.
The COVID-19 Genomics U.K. Consortium has become a global model for analyzing genomes for signs that the coronavirus is gaining power to spread — or to kill.
